The $100m venture financing of NewMed Medical was the medical devices industry’s top cross border venture financing deal as total deals worth $616.92m were announced globally in March 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 75% over the previous month of $352.63m and a rise of 53.1% when compared with the last 12-month average, which stood at $402.86m.
Comparing cross border venture financing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $310.51m. At the country level, the US topped the list in terms of deal value at $244m.
In terms of volumes, North America emerged as the top region for medical devices industry cross border venture financing deals globally, followed by Middle East and Africa and then Asia-Pacific.
The top country in terms of cross border venture financing deals activity in March 2021 was the Israel with eight deals, followed by the US with eight and Canada with two.
In 2021, as of March, medical devices cross border venture financing deals worth $1.18bn were announced globally, marking an increase of 9.9% year on year.
medical devices industry cross border venture financing deals in March 2021: Top deals
The top five medical devices industry cross border venture financing deals accounted for 54.6% of the overall value during March 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $337m, against the overall value of $616.92m recorded for the month.
The top five medical devices industry cross border venture financing deals of March 2021 tracked by GlobalData were:
1) Boyuan Capital, Dachen Caizhi, Junzi Capital, Orbimed Advisors, Temasek Holdings (Private), Yunfeng Capital and Zhang Kelingyi’s $100m venture financing of NewMed Medical
2) The $82m venture financing of Scipher Medicine by Alumni Ventures Group, aMoon Partners, Echo Health Ventures, Khosla Ventures and Northpond Ventures
3) Ambix Life Science Fund I and MedVenture Partners’ $65m venture financing of CorVista Health
4) The $50m venture financing of TytoCare by Insight Partners, Olive Tree Ventures, Qualcomm Ventures, Qumra Capital, Shenzhen Capital Group and Tiger Global Management
5) Ally Bridge Group’s venture financing of RefleXion Medical for $40m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.